Declaratory Judgment Ruling From U.S. Supreme Court Could Impact Licensing Deals, ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
High court is mulling MedImmune's right to challenge a patent licensed from Genentech while continuing to make royalty payments.
You may also be interested in...
Genentech/MedImmune Patent Case Could Spur Tighter Licensing Deals
Supreme Court ruling that MedImmune can challenge the validity of a patent it had licensed could also encourage generic firms to seek declaratory judgments.
Genentech/MedImmune Patent Case Could Spur Tighter Licensing Deals
Supreme Court ruling that MedImmune can challenge the validity of a patent it had licensed could also encourage generic firms to seek declaratory judgments.
MedImmune Expects Initial Data From Head-To-Head Numax/Synagis Trial Before Nov. 23
While the firm anticipates a superiority finding, the study comparing its RSV therapies is powered for both superiority and non-inferiority, MedImmune execs say during Q3 call.